IMIDomics, a Vall d'Hebron spin-off founded in 2015 by Dr. Sara Marsal, head of the Rheumatology Service at Vall d'Hebron University Hospital and head of the Rheumatology research group at Vall d'Hebron Research Institute, has received an equity investment from Evotec SE, a world leader in drug development.

IMIDomics is a privately held global biotechnology company focused on the discovery and development of new targets and drugs for the treatment of patients with immune-mediated inflammatory diseases (IMIDs). Last June it completed a $16.5 million financing round in which DNS Capital, Bristol Myers Squibb, The Pritzker Organization and TAO Capital, among others, participated.

This new investment will further advance IMIDomics’ Precision Discovery™ Engine which enables a deep understanding of how IMIDs work within patients via a combination of clinical and computational expertise with patient biological samples from the Vall d’Hebron Hospital IMID Biobank, exclusive access to curated, secure and anonymized clinical data collected from more than 17,000 IMID patients and control subjects from across 150 health centers, and proprietary biomolecular signatures generated by IMIDomics from these same patients. Ultimately, the Engine’s purpose is to discover medicines that will materially impact IMID patients’ lives.